← Back to all signals
RESEARCH PAPER ANALYSIS

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.

AI interpretation is pending for this paper.

Open original publication →
PMID39046786
JournalBlood
Publication Date2024-10-31
Ingested2026-08-02 12:02 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

Although tyrosine kinase inhibitor (TKI) therapy has markedly improved the survival of people with chronic-phase chronic myeloid leukemia (CML), 20% to 30% of people still experienced therapy failure. Data from 1955 consecutive patients with chronic-phase CML diagnosed by the European LeukemiaNet recommendations from 1 center receiving initial imatinib or a second-generation (2G) TKI therapy were interrogated to develop a clinical prediction model for TKI-therapy failure. This model was subsequently validated in 3454 patients from 76 other centers. Using the predictive clinical covariates associated with TKI-therapy failure, we developed a model that stratified patients into low-, intermediate- and high-risk subgroups with significantly different cumulative incidences of therapy failure (P < .001). There was good discrimination and calibration in the external validation data set, and the performance was consistent with that of the training data set. Our model had the better prediction discrimination than the Sokal and European Treatment and Outcome Study long-term survival scores, with the greater time-dependent area under the receiver-operator characteristic curve values and a better ability to redefine the risk of therapy failure. Our model could help physicians estimate the likelihood of initial imatinib or 2G TKI-therapy failure in people with chronic-phase CML.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 Comparison of Phenol Application and Endoscopic Pilonidal Sinus Treatment in Pediatric Pilonidal Sinus Disease. Pediatrics international : official journal of the Japan Pediatric Society 63.74 2 Unfinished Business and Experiences of Bereaved Families of Patients with Cancer: A Cross-Sectional Survey. Palliative medicine reports 61.0 3 The 21st International ``Ponte di Legno'' Childhood Acute Lymphoblastic Leukemia Workshop Report: Progress and Emerging Opportunities. Clinical lymphoma, myeloma & leukemia 49.0 4 Acute Leukemia During the First Six Months of Life: A Population-Based Analysis of Survival by Leukemia Type. Clinical lymphoma, myeloma & leukemia 64.12 5 Pediatric orbital solitary fibrous tumor/hemangiopericytoma presenting with isolated eyelid edema: a case report. Frontiers in pediatrics 53.1 6 Malignancies in patients with inborn errors of immunity: insights from 20-years of clinical experience in Qatar. Frontiers in immunology 68.6 7 Precision medicine and parental experience: a longitudinal study of psychosocial responses to germline genomic results in pediatric oncology. Frontiers in medicine 67.36 8 Cytokine-augmented risk stratification for six-month incident nephritis in children with IgA vasculitis. Frontiers in pediatrics 58.5 9 Time-bounded uncertainty in childhood cancer survivorship: a psycho-oncology perspective on result communication. Frontiers in psychology 57.0 10 "From misdiagnosis to precision medicine: strengthening pediatric neuro-oncology care in LMICs toward equitable pLGG outcomes". Frontiers in oncology 75.5 11 Practical Guidance on Initiating and Switching Targeted Immunotherapies in Generalised Myasthenia Gravis: A German-Austrian Expert Opinion Paper. European journal of neurology 66.4 12 Technical Considerations for Robotic Pediatric Lobectomy. Annals of thoracic surgery short reports 54.0 13 Kaposi Sarcoma-Associated Herpesvirus Is Not Detected in Osteosarcoma From KSHV-Endemic African Countries and the Non-Endemic United States Populations. Journal of medical virology 59.5 14 ELISA (Embedding-Linked Interactive Single-cell Agent): an interpretable hybrid generative Artificial Intelligence agent for expression-grounded discovery in single-cell genomics. Briefings in bioinformatics 48.5 15 Thyroid Cancer in the Modern Era: From Molecular Landscape and Multimodal Diagnostics to Integrative Traditional Chinese Medicine-A Comprehensive Review. Cancer management and research 90.6 16 Presumed left atrial myxoma presenting with seizures, massive stroke, and systemic embolization in an adolescent: a case report. International journal of emergency medicine 49.0 17 Ewing's Sarcoma in Adults: A Predictive Nomogram and Survival Analysis of a Cohort of 937 Patients. Journal of surgical oncology 73.92 18 Comments on "Initial Cerebrospinal Fluid Blast Clearance Rate in Pediatric B-Lymphoblastic Leukemia Is Associated With Overall Survival". Journal of pediatric hematology/oncology 49.12 19 Impact of Number of Lymph Nodes Sampled and Density of Positive Nodes on Outcomes Among Over 2000 Patients With Stage I to III Favorable Histology Wilms Tumor Enrolled on AREN03B2: A Children's Oncology Group Renal Tumor Study. Annals of surgery 70.5 20 Prognostic impact of risk organ involvement and metabolic parameters assessed by staging 18F-FDG PET/CT in pediatric Langerhans cell histiocytosis. Nuclear medicine communications 63.3 21 Prognostic value of plasma thymus- and activationregulated chemokine levels after the second cycle of chemotherapy in pediatric Hodgkin lymphoma. Haematologica 55.44 22 Germline lymphoma-predisposing variants: impact on age of cancer diagnosis and survival in pediatric patients. Haematologica 51.12 23 Excess mortality convergence after paediatric allogeneic transplantation: a caveat for the right to be forgotten. Comment on: "Decreasing excess mortality after allogeneic stem cell transplantation for acute leukemia". Haematologica 49.5 24 EARLY DISCONTINUATION OF ANTIBIOTICS IN PEDIATRIC PATIENTS WITH LOW- AND HIGH-RISK FEBRILE NEUTROPENIA: A SINGLE-CENTRE EXPERIENCE. Journal of the Pediatric Infectious Diseases Society 68.4 25 Comment on "How I Approach Anxiety in Children and Teens with Cancer". Pediatric blood & cancer 47.5 26 Progressive Tracheal Injury Following Tumor Regression in a Child With T-Cell Lymphoblastic Lymphoma. Pediatric blood & cancer 28.5 27 Very Late Relapse of Acute Myeloid Leukemia With a Rare HNRNPH1::MLLT10 Fusion Following a Pediatric Myeloid Neoplasm: A Successful Venetoclax-Azacitidine Bridge to Hematopoietic Stem Cell Transplantation. Pediatric blood & cancer 49.12 28 Interventions to Reduce Financial Toxicity of Childhood, Adolescent, and Young Adult Cancer Survivors: A Scoping Review. Pediatric blood & cancer 61.32 29 ENCERT: A Multisite Phase 1 Trial Using Everolimus in Combination With Nelarabine, Cyclophosphamide, and Etoposide in Relapsed T-Cell Lymphoblastic Leukemia/Lymphoma. Pediatric blood & cancer 87.42 30 Advanced Radiotherapy Across a Multi-Geography Referral Network for Children With Ewing Sarcoma and Rhabdomyosarcoma: Treatment Delivery and Early Outcomes-A Single-Centre Experience. Pediatric blood & cancer 72.88 31 Genomic Characterization of ETV6::RUNX1-Positive Childhood B-ALL in a Chinese Cohort: Novel Fusion Partners, Co-Occurring Mutations, and Risk-Stratifying Biomarkers. Pediatric blood & cancer 59.75 32 Diagnostic Yield of Brain MRI in Pediatric Short Stature: Hypothalamic-Pituitary Lesions and Incidental Findings in Real-World Practice. Clinical endocrinology 67.3
PATIENT-FRIENDLY SUMMARY

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.

For education only—not personal medical advice.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic